Collaboration with Merck $MRK to discover &amp; develop proprietary influenza A/B antiviral agents.

💰 A/B program could provide up to $156M in milestone payments.

The research &amp; collaboration w $MRK also provides royalties follow  commercialization of CC-42344: Influenza A Program